Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly

by Zacks Equity Research

Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL

by Kinjel Shah

Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951

The Zacks Analyst Blog Highlights Lilly, Honeywell International. American Express, Lowe's Companies and Airbnb

by Zacks Equity Research

Lilly, Honeywell International. American Express, Lowe's Companies and Airbnb are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Eli Lilly, Honeywell International & American Express

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Honeywell International Inc. (HON) and American Express Co. (AXP).

Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device

by Zacks Equity Research

Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.

Here's Why You Should Add Novo (NVO) Stock to Your Portfolio

by Zacks Equity Research

Novo (NVO), a top-ranked stock at present, enjoys a strong foothold in the Diabetes Care market with increasing market shares driven by Rybelsus, Ozempic and Victoza's strong performance.

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $331.08, moving -0.76% from the previous trading session.

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%

by Zacks Equity Research

Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Eli Lilly (LLY) closed at $329.47, marking a +0.73% move from the previous day.

Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%

by Zacks Equity Research

Novo Nordisk (NVO) plans to lower prices of several pre-filled insulin pens and vials by up to 75% in the United States. However, the company plans not to start this until January 2024.

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK

by Kinjel Shah

FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $316.85 in the latest trading session, marking a +1.38% move from the prior day.

Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study

by Zacks Equity Research

Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.

Lilly's (LLY) Verzenio Gets FDA Nod for Expanded Breast Cancer

by Zacks Equity Research

Eli Lilly (LLY) announces FDA approval of label expansion of Verzenio (abemaciclib), in combination with endocrine therapy, for treating HR+, HER2-, node-positive and high-risk early breast cancer.

Incyte (INCY) Discontinues Jakafi Combo Myelofibrosis Study

by Zacks Equity Research

Incyte (INCY) decides to scrap the LIMBER-304 study evaluating the efficacy and safety of parsaclisib plus Jakafi for myelofibrosis (MF) following an independent data monitoring committee recommendation.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

by Zacks Equity Research

The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH